Biocept Culture d’entreprise

Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has more than 25 years of leadership experience in healthcare sales, marketing, operations and reimbursement. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. He served as Account Executive at Impath. Prior to joining Biocept, He served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement. He joined Clarient in 2002 when it was a small publicly traded company and served in several leadership roles including Director, Vice President of Sales, Vice President of Sales and Reimbursement and finally GM. During the time, he was with Clarient, company grew to over $110 million in revenue and was acquired by GE Healthcare. Prior to joining Clarient, He was with Impath, an innovative cancer diagnostic company. He has been a Director at Biocept, Inc. since 2013. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (also known as the University of Central Missouri).

Dr. Veena M. Singh, M.D., has been a Senior Vice President and Senior Medical Director of Biocept, Inc., since December 2014. Dr. Singh has years of experience in laboratory diagnostics and a deep personal interest in blood-based biomarker testing. Prior to joining Biocept, Dr. Singh led the clinical laboratory team as the Medical Director at bioTheranostics since July 2009, where she oversaw growth in the CLIA laboratory test menu to incorporate offerings in solid tumor molecular analysis utilizing multiple methodologies and platforms including Next Generation Sequencing, RT-PCR and FISH. In addition, she has a wealth of experience in regulatory compliance (FDA, IVDMIA and Companion Diagnostics) and reimbursement. She serves as a Member of Scientific Advisory Board at Biocept, Inc. She completed a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles and an Anatomic and Clinical pathology residency at the University of California, San Diego. Dr. Singh is board certified in Anatomic and Clinical Pathology and Molecular Genetic Pathology. Dr. Singh was an expert panel member of the CAP/ASCO/ASCP colorectal cancer testing guideline committee. Dr. Singh obtained her medical degree from the University of Transkei, South Africa.

Mr. David F. Hale is Founder and Managing Director of Dermata Therapeutics, LLC. Mr. Hale serves as Advisor at Windamere Venture Partners, LLC. He is a co-founder of CONNECT. He serves as the Chairman and Chief Executive Officer at Hale BioPharma Ventures, LLC. He is Co-Founder of Neurelis, Inc. and serves as its Chairman and Chief Executive Officer. He co-founded Pernix Sleep, Inc. in August 2003 and served as its interim Chief Executive Officer from January 2008 to August 2008 and Executive Chairman since August 2003. He served as Principal Executive Officer of Biocept, Inc. until August 26, 2013. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as the Chief Operating Officer, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997, he was Chairman, President and Chief Executive Officer of Gensia, Inc., and a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. Prior to joining Hybritech, he served as Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. He served as Chief Executive Officer and President at CancerVax Corp. since October 2000. He served as Executive Chairman and Acting Principal Executive Officer of Metabasis Therapeutics, Inc. since September 1, 2009 and October 30, 2009 respectively. He serves as Chairman at Ridge Diagnostics, Inc., The Board at CRISI Medical Systems, Inc., Advantar Laboratories, Inc., Intrepid Therapeutics, Inc., Colorescience, Inc., Katama Pharmaceuticals, Skylit Medical and Agility Clinical, Inc. He has been the Chairman of Conatus Pharmaceuticals Inc. since December 2012 and has been its Director since October 2006. He serves as Chairman of Oncternal Therapeutics, Inc. He has been a Non-Executive Chairman at Biocept, Inc. since February 10, 2014 and served as its Executive Chairman from March 2011 to February 10, 2014. He also serves as Chairman of the Board of Trustees of Rady Children's Hospital. Mr. Hale served as Chairman of Santarus, Inc. from February 2004 to January 2, 2014 and served as its Director from June 2000 to January 2, 2014. He served as the Executive Chairman of SkinMedica, Inc. from March 2003 to 2012 and served as its Director from 2001 to 2012. He served as Chairman of Metabasis Therapeutics, Inc. since September 14, 2006 and served as its Independent Director since April 1997. He served as Chairman of Micromet, Inc. from May 2006 to March 2, 2012. He serves as a Director of CONNECT. He serves as Trustee at Sanford-Burnham Medical Research Institute. He serves as Director at Biotechnology Institute, The. He serves as Life Director at BIOCOM, Inc. He serves as Director at Verus Pharmaceuticals, Inc. and Adigica Health, Inc. He serves as a Director of Neurelis, Inc. Mr. Hale serves as a Director of Dermata Therapeutics, LLC. He served as a Non Executive Independent Director of Cassiopea S.p.A. since April 2015 until October 24, 2017. He served as a Director of Tokalas, Inc. He served as Director of Dura Pharmaceuticals, Inc. since 1986. He served as Director at CancerVax Corp. since December 2000, Xcel Pharmaceuticals Inc. since November 2001 and Micromet, Inc. from December 2000 to March 7, 2012. Mr. Hale received a Bachelor of Arts degree in Biology and Chemistry from Jacksonville State University. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc. He also serves as Chairman of Clarify Medical, Inc., MDRejuvena, Inc., Neurana Pharmaceuticals, Inc. and Recros Medica, Inc. He was President and Chief Executive Officer of Women First HealthCare, Inc. from late 1997 to June 2000, before joining CancerVax in October 1999.

Dr. Lyle J. Arnold, Ph.D. has been the Chief Scientific Officer and Senior Vice President of Research & Development at Biocept, Inc. since May 2011. Dr. Arnold serves as an Independent Consultant. Dr. Arnold founded Aegea Biotechnologies. He served as a Vice President of Research at Gen Probe Inc. since September 22, 2003 October 2009. He was also associated at Gen-Probe from 1985 to 1989 as Head of technology research. Previously, he held senior scientific and management positions at Molecular Biosystems, Genta, Synteni, Incyte Genomics and Oasis Biosciences, where he was President and Chief Scientific Officer from October 2001 to September 2003. He serves as a Member of Scientific Advisory Board at Biocept, Inc. He served as a Director at Asuragen, Inc., since March 30, 2010 until January 10, 2017. In addition, he was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. In addition, he has authored more than 50 scientific publications. He is the principal inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies core to Hologic assays that generate more than $500M in product revenue annually. Dr. Arnold is also the inventor of the patented Switch-Blocker technology for detecting extremely rare genetic events that Biocept uses for interrogating ctDNA for cancer associated mutations. Dr. Arnold received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.

Dr. Soonkap Hahn Ph.D. serves as Chief Executive Officer and President of Novatrix Biomedical, Inc. Dr. Hahn served as the Chief Technical Officer of Biocept Inc. Dr. Hahn founded Biocept Inc. in 1997 and served as its Chief Operating Officer. He founded Novatrix Medical Corporation in 1993, where he served as a Vice President of Research and Development and Chief Technical Officer until 1997. Dr. Hahn's technical experience includes medical device, drug delivery and drug discovery technologies. From 1987 to 1993, Dr. Hahn held positions of increasing technical and scientific responsibility with Vitaphore Corporation, Fox's Lab and Gensia Inc. as principal chemist and scientific investigator. Dr. Hahn led numerous technical development programs in life science-based companies. He is an inventor on over 15 patents. He served as Director of Biocept Inc. Dr. Hahn received his Ph.D. in Organic Chemistry from Ohio State University and performed Post-Doctoral Research at Stanford University with Professor Carl Djerassi in 1986.

Tom Burns serves as the VP, Operations of Biocept, Inc. - Personalized Medicine From a Liquid Biopsy. Tom started at Biocept, Inc. - Personalized Medicine From a Liquid Biopsy in December of 2003. Tom currently resides in Greater San Diego Area.

Cory Dunn serves as the Vice President Marketing of Biocept, Inc. - Personalized Medicine From a Liquid Biopsy. Cory started at Biocept, Inc. - Personalized Medicine From a Liquid Biopsy in October of 2018. Cory currently resides in Greater San Diego Area.

Lyle Arnold serves as the Senior VP, R&D and CSO of Biocept, Inc. - Personalized Medicine From a Liquid Biopsy. Lyle started at Biocept, Inc. - Personalized Medicine From a Liquid Biopsy in May of 2011. Lyle currently resides in the Greater San Diego Area.